GM. Ray, C. Rodriguez, SM. Schulman, P. Sarangarm, M. Bardack and MF. Bouchonville (2019). Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis. Clinical practice and cases in emergency medicine, 3(2), 140-143. https://doi.org/10.5811/cpcem.2019.2.41795

PubMed 31061971

[Abstract]
Empagliflozin is a sodium glucose cotransporter-2 inhibitor that inhibits renal glucose reabsorption through an insulin-independent mechanism. This class of drugs is used in the management of type 2 diabetes. A 49-year-old female with type 2 diabetes treated with empagliflozin presented to the emergency department in diabetic ketoacidosis (DKA). This case report details the series of events leading to the diagnosis of drug-induced DKA, which led to a change in the patient's diagnosis from type 2 diabetes to type 1 diabetes.